Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia. Testing for minimal residual ...

VENLO, Netherlands–(BUSINESS WIRE)–$QGEN #QIAGEN–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics ...

Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for ...

Foundation Medicine adds a tissue-informed whole genome sequencing molecular residual disease test to its portfolio of high-quality testing solutions.

MORRISVILLE, N.C., July 30, 2025--(BUSINESS WIRE)--SAGA Diagnostics, a pioneer in blood-based cancer testing redefining the standard for ultra-sensitive molecular residual disease (MRD) detection, ...

In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.

An innovative approach could transform the treatment landscape for DLBCL patients, offering hope to those who might otherwise ...

The demand for minimal residual disease testing is increasing mainly due to the higher prevalence of solid tumors and blood cancers like leukemia, multiple myeloma, and lymphoma. Continuous advances ...

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Adaptive Biotechnologies (NASDAQ:ADPT) delivered strong second-quarter results that exceeded analyst expectations, with its Minimal Residual Disease (MRD) business reaching a significant profitability ...